BioMarin Pharmaceuticals
BMRN
BMRN
429 hedge funds and large institutions have $14.6B invested in BioMarin Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 147 increasing their positions, 158 reducing their positions, and 53 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
8% less capital invested
Capital invested by funds: $15.8B → $14.6B (-$1.2B)
22% less call options, than puts
Call options by funds: $76.6M | Put options by funds: $97.9M
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Holders
429
Holding in Top 10
9
Calls
$76.6M
Puts
$97.9M
Top Buyers
| 1 | +$285M | |
| 2 | +$136M | |
| 3 | +$103M | |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$84.7M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$70.6M |
Top Sellers
| 1 | -$148M | |
| 2 | -$76.2M | |
| 3 | -$57.8M | |
| 4 |
JPMorgan Chase & Co
New York
|
-$42.8M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$39M |